← Targeted Therapeutics
Specialty therapeutic
Tepadina (thiotepa)
A thiotepa-based specialty medicine listed in Ribicon’s former therapeutic portfolio.
Product overview
What it is.
- Active substance: thiotepa, supplied as a powder made up into a solution for infusion (drip into a vein).
- Used in combination with other chemotherapy medicines.
- As a conditioning (preparative) treatment before hematopoietic progenitor cell transplantation in patients with blood diseases, including leukemia, or diseases causing low red blood cell counts such as thalassemia or sickle-cell anaemia.
- During treatment of solid tumors when high-dose chemotherapy followed by hematopoietic progenitor cell transplantation is needed.
Specifications
Key figures.
- Strengths listed
- 15 mg, 100 mg, 200 mg, 400 mg
Portfolio information
From the original portfolio.
Content review draft
The former site discusses use in conditioning before stem-cell transplantation and in selected oncology settings. Local authorization and approved indications must be checked before publication.
This page preserves the former site’s product information for review. It does not establish current Canadian availability, approved indications, performance, or prescribing information. Request verified documentation before relying on it.
Request verified informationExplore this area